PROSPERI DAVIDE

Banfi, A., Barbieri, L., Fiandra, L., Salvioni, L., Innocenti, M., Prosperi, D. (2025). Dual-Targeting Strategy to Repurpose Cetuximab with HFn Nanoconjugates for Immunotherapy of Triple-Negative Breast Cancer. Intervento presentato a: Next Gen3ration research - September 18-19, 2025, Genoa, Italy. Dettaglio

Banfi, A., Salvioni, L., Prosperi, D. (2025). Harnessing Mirror Image Peptides: nanovector for Nucleic Acids delivery in cancer treatment. Intervento presentato a: TeCSBi PhD Meeting 2025, Varese, Italy. Dettaglio

Barbieri, L., Salvioni, L., Banfi, A., Garbujo, S., Fiandra, L., Baioni, C., et al. (2025). Dual-Targeting Strategy to Repurpose Cetuximab with HFn Nanoconjugates for Immunotherapy of Triple-Negative Breast Cancer. ACS APPLIED MATERIALS & INTERFACES, 17(23), 33648-33663 [10.1021/acsami.5c06626]. Dettaglio

Sinesi, G., Salvioni, L., Ronchi, E., Barbuzzi, E., Prosperi, D., Colombo, M., et al. (2025). Exploring Bovine Serum Albumin (BSA) as a Facile Substrate for Testing of Osmolytes as Cosmetic Ingredients. MOLECULES, 30(3) [10.3390/molecules30030664]. Dettaglio

Colombo, M., Fiandra, L., Alessio, G., Mazzucchelli, S., Nebuloni, M., Palma, C., et al. (2024). Tumour Homing and Therapeutic Effect of Colloidal Nanoparticles Depend on the Number of Attached Antibodies. In W. Parak (a cura di), Bio-Nano Interfaces: Perspectives, Properties, and Applications (pp. 427-470). Jenny Stanford Publishing [10.1201/9781003306498-22]. Dettaglio